Phase II study of induction chemotherapy with gemcitabine plus 5-fluorouracil followed by gemcitabine-based concurrent chemoradiotherapy for unresectable locally advanced pancreatic cancer

Simple item page
dc.contributor.buuauthorKurt, Ender
dc.contributor.buuauthorKurt, Meral
dc.contributor.buuauthorKanat, Özkan
dc.contributor.buuauthorÇetintaş, Sibel Kahraman
dc.contributor.buuauthorAygun, Sevilcan
dc.contributor.buuauthorPalazoğlu, Julay
dc.contributor.buuauthorÖzkan, Lütfi
dc.contributor.buuauthorEvrensel, Türkkan
dc.contributor.buuauthorKaya, Ekrem
dc.contributor.buuauthorManavoğlu, Osman
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Radyasyon Onkolojisi Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Cerrahisi Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-9732-5340tr_TR
dc.contributor.orcid0000-0002-9562-4195tr_TR
dc.contributor.orcid0000-0003-1637-910Xtr_TR
dc.contributor.researcheridAAJ-1027-2021tr_TR
dc.contributor.researcheridAAG-7319-2021tr_TR
dc.contributor.researcheridAAA-7047-2020tr_TR
dc.contributor.researcheridAAA-3961-2020tr_TR
dc.contributor.scopusid7006207332tr_TR
dc.contributor.scopusid8843050600tr_TR
dc.contributor.scopusid55881548500tr_TR
dc.contributor.scopusid6505881756tr_TR
dc.contributor.scopusid15833990600tr_TR
dc.contributor.scopusid15835427400tr_TR
dc.contributor.scopusid55915679400tr_TR
dc.contributor.scopusid6603942124tr_TR
dc.contributor.scopusid7004568109tr_TR
dc.contributor.scopusid6602587152tr_TR
dc.date.accessioned2021-10-14T11:00:10Z
dc.date.available2021-10-14T11:00:10Z
dc.date.issued2006
dc.description.abstractAims and background: To evaluate the efficacy and tolerability of a new treatment approach including induction chemotherapy (CT) and concurrent chemoradiotherapy (CRT) in unresectable, locally advanced pancreatic cancer (LAPC). Patients and methods: Twenty-four patients with LAPC were enrolled in the study. They first received induction CT consisting of 5-fluorouracil (5FU) (500 mg/m(2)) and gemcitabine (1000 mg/m(2)), which were given weekly for 3 weeks of every 4. Patients showing a response or disease stabilization after 2 cycles of induction CT received CRT consisting of external beam radiotherapy (50.4-54 Gy in fractions of 1.8 Gy/day) and gemcitabine (350 mg/m(2), weekly for 6 weeks). Patients without disease progression received 2 additional cycles of CT consisting of 5FU plus gemcitabine with the same doses and schedule as given in the induction CT. Results: After the end of the study, 2 (13%) and 5 (21%) patients showed complete and partial responses, respectively. Five patients (21%) had disease stabilization. The grade 3 and 4 toxicities associated with CT were neutropenia (21%) and thrombocytopenia (4%). The grade 3 and 4 toxicities occurring in patients who received CRT were neutropenia (24%), thrombocytopenia (24%), diarrhea (18%), and nausea (12%). The median progression-free survival for all patients was 6 months (95% Cl, 3.6-8.4), and the median overall survival was 11 months (95% Cl, 8.16-13.84). Conclusions: The CRT approach of this study is moderately active and has an acceptable toxicity profile. However, the incorporation of combination CT into CRT at the present schedule could not produce any additional benefit over CRT alone. Newer agents with more systemic activity are clearly warranted.en_US
dc.identifier.citationKurt, E. vd. (2006). ''Phase II study of induction chemotherapy with gemcitabine plus 5-fluorouracil followed by gemcitabine-based concurrent chemoradiotherapy for unresectable locally advanced pancreatic cancer''. Tumori, 92(6), 481-486.en_US
dc.identifier.endpage486tr_TR
dc.identifier.issn0300-8916
dc.identifier.issue6tr_TR
dc.identifier.pubmed17260487tr_TR
dc.identifier.scopus2-s2.0-33846599761tr_TR
dc.identifier.startpage481tr_TR
dc.identifier.urihttps://doi.org/10.1177/030089160609200603
dc.identifier.urihttps://journals.sagepub.com/doi/10.1177/030089160609200603
dc.identifier.urihttp://hdl.handle.net/11452/22344
dc.identifier.volume92tr_TR
dc.identifier.wos000243575200003tr_TR
dc.indexed.pubmedPubmeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherWichtig Publishingen_US
dc.relation.journalTumoritr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectOncologyen_US
dc.subjectPancreatic carcinomaen_US
dc.subjectInduction chemotherapyen_US
dc.subjectChemoradiotherapyen_US
dc.subjectResectionen_US
dc.subjectCombinationen_US
dc.subjectChemoradiationen_US
dc.subjectSurvivalen_US
dc.subjectRadiotherapyen_US
dc.subjectCarcinomaen_US
dc.subjectTrialen_US
dc.subjectRadiation-therapyen_US
dc.subjectCooperative-oncology-groupen_US
dc.subject.emtreeGfluorouracilen_US
dc.subject.emtreeGemcitabineen_US
dc.subject.emtreeFluorouracilen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAdvanced canceren_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeAnemiaen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeBolus injectionen_US
dc.subject.emtreeCancer combination chemotherapyen_US
dc.subject.emtreeCancer radiotherapyen_US
dc.subject.emtreeCancer survivalen_US
dc.subject.emtreeClinical articleen_US
dc.subject.emtreeClinical trialen_US
dc.subject.emtreeControlled clinical trialen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDiarrheaen_US
dc.subject.emtreeDisease courseen_US
dc.subject.emtreeDrug dose reductionen_US
dc.subject.emtreeDuodenum ulceren_US
dc.subject.emtreeExternal beam radiotherapyen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMucosa inflammationen_US
dc.subject.emtreeNauseaen_US
dc.subject.emtreeNeutropeniaen_US
dc.subject.emtreePancreas canceren_US
dc.subject.emtreeThrombocytopeniaen_US
dc.subject.emtreeTreatment responseen_US
dc.subject.emtreePhase 2 clinical trialen_US
dc.subject.scopus130-Nm Albumin-Bound Paclitaxel; Gemcitabine; Pancreatic Neoplasmsen_US
dc.subject.wosOncologyen_US
dc.titlePhase II study of induction chemotherapy with gemcitabine plus 5-fluorouracil followed by gemcitabine-based concurrent chemoradiotherapy for unresectable locally advanced pancreatic canceren_US
dc.typeArticle

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus